Tiziana Life Sciences (TLSA) Announces Submission of Patent Application for Nasal Administration of Foralumab for Treatment of COVID-19 Patients

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. FDX
3. ABBV
4. META
5. SPY
6. ACN
7. BLZE
8. IBM
9. NKE
10. MU

Go back to Tiziana Life Sciences (TLSA) Announces Submission of Patent Application for Nasal Administration of Foralumab for Treatment of COVID-19 Patients

Tiziana Life Sciences plc: Tiziana Announces Submission of a Patent Application for Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, for Treatment of COVID-19 Patients

July 31, 2020 2:00 AM EDT

NEW YORK and LONDON, July 31, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (Tiziana or the Company), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, is pleased to announce that it has submitted a patent application for the potential use of nasally administered Foralumab, a fully human anti-CD3 monoclonal antibody (mAb), for the treatment of COVID-19 either alone or in combination with other anti-viral drugs. Recent clinical studies imply that a combination of anti-inflammatory and anti-viral drugs may be more effective to treat patients at different... More